Skip to main content
Premium Trial:

Request an Annual Quote

Boston Heart Diagnostics LipidSeq

Boston Heart Diagnostics, a Eurofins company, has launched the LipidSeq genetic test for cardiovascular disease. A saliva-based, 23-gene, next-generation sequencing test, LipidSeq identifies the most common genetic causes of lipid and lipoprotein disorders associated with premature cardiovascular, pancreatic, kidney, and neurological diseases. Specific conditions detected by the test include familial forms of hypercholesterolemia, lysosomal acid lipase deficiency, sitosterolemia, cerebrotendinous xanthomatosis, dysbetalipoproteinemia, hypertriglyceridemia, and HDL deficiency states including ApoA-I deficiency, Tangier disease, and LCAT deficiency.

LipidSeq was developed in collaboration with Eurofins laboratory partner Clinical Enterprise, which performs the genetic sequencing, and in consultation with Robert Hegele of Robarts Research Institute in London, Ontario.